What is the address of RIXPHARMA?

The registered office of RIXPHARMA is located at Avenue John Kennedy 45, 1330 Rixensart.

Is RIXPHARMA still active?

Yes. According to the CBE (30 September 2026) RIXPHARMA is active, legal situation “Normale toestand”, started on 26 June 2006.

Is RIXPHARMA registered on Peppol?

Yes, RIXPHARMA is registered on the Peppol network with ID 0208:0882172240.

What is the enterprise number of RIXPHARMA?

The enterprise number of RIXPHARMA is BE0882172240.

When was RIXPHARMA founded?

RIXPHARMA was founded on 26 June 2006.

Who are the directors of RIXPHARMA?

According to the 2025 annual accounts, the directors of RIXPHARMA are: Thibault Bataille.

Is RIXPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 June 2006; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did RIXPHARMA make in 2025?

RIXPHARMA recorded a loss after taxes of € 5,655 in financial year 2025.

What is the revenue of RIXPHARMA?

As a small company, RIXPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -5,255.

RIXPHARMA (Private Limited) - Rixensart - BE0882172240

Dossier RIXPHARMA, printed on 30 September 2026 from databakkes.be/en/0882172240/rixpharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

RIXPHARMA from Rixensart, company number BE0882172240, closed financial year 2025 with a result of € -5,655 after tax. For that financial year RIXPHARMA recorded a gross margin of € -5,255 and equity of € 107,377. Compared with financial year 2024, the result moved from € -3,643 to € -5,655. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.

What it is worth Healthy

€ 107,377

▼ 5% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -5,655

▼ 55 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 114,500

▼ 68% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 11,177.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 792

Supplier invoices still open on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 8,082 Gross margin 2022: € 8,082 First fiscal year in the series	€ 8,254 Gross margin 2023: € 8,254 ▲ 2% vs 2022 (€ 8,082) Favourable step	€ -3,256 Gross margin 2024: € -3,256 ▼ € 11,510 vs 2023 (€ 8,254) Unfavourable step	€ -5,255 Gross margin 2025: € -5,255 ▼ € 1,999 vs 2024 (€ -3,256) Unfavourable step	▼ € 1,999
Profit after taxes	€ -4,213 Profit after taxes 2022: € -4,213 First fiscal year in the series	€ 7,253 Profit after taxes 2023: € 7,253 ▲ € 11,466 vs 2022 (€ -4,213) Favourable step	€ -3,643 Profit after taxes 2024: € -3,643 ▼ € 10,896 vs 2023 (€ 7,253) Unfavourable step	€ -5,655 Profit after taxes 2025: € -5,655 ▼ € 2,012 vs 2024 (€ -3,643) Unfavourable step	▼ € 2,012
Equity	€ 109,422 Equity 2022: € 109,422 First fiscal year in the series	€ 116,676 Equity 2023: € 116,676 ▲ 7% vs 2022 (€ 109,422) Favourable step	€ 113,032 Equity 2024: € 113,032 ▼ 3% vs 2023 (€ 116,676) Unfavourable step	€ 107,377 Equity 2025: € 107,377 ▼ 5% vs 2024 (€ 113,032) Unfavourable step	▼ 5%
Total debts	€ 83,874 Total debts 2022: € 83,874 First fiscal year in the series	€ 312,427 Total debts 2023: € 312,427 ▲ 272% vs 2022 (€ 83,874) Unfavourable step	€ 244,887 Total debts 2024: € 244,887 ▼ 22% vs 2023 (€ 312,427) Favourable step	€ 45,679 Total debts 2025: € 45,679 ▼ 81% vs 2024 (€ 244,887) Favourable step	▼ 81%
Cash	€ 153,930 Cash 2022: € 153,930 First fiscal year in the series	€ 428,671 Cash 2023: € 428,671 ▲ 178% vs 2022 (€ 153,930) Favourable step	€ 357,920 Cash 2024: € 357,920 ▼ 17% vs 2023 (€ 428,671) Unfavourable step	€ 114,500 Cash 2025: € 114,500 ▼ 68% vs 2024 (€ 357,920) Unfavourable step	▼ 68%
Land & buildings	€ 36,485 Land & buildings 2022: € 36,485 First fiscal year in the series	-	-	-
Retained profit	€ 13,222 Retained profit 2022: € 13,222 First fiscal year in the series	€ 20,476 Retained profit 2023: € 20,476 ▲ 55% vs 2022 (€ 13,222) Favourable step	€ 16,832 Retained profit 2024: € 16,832 ▼ 18% vs 2023 (€ 20,476) Unfavourable step	€ 11,177 Retained profit 2025: € 11,177 ▼ 34% vs 2024 (€ 16,832) Unfavourable step	▼ 34%
Balance sheet total	€ 193,296 Balance sheet total 2022: € 193,296 First fiscal year in the series	€ 429,103 Balance sheet total 2023: € 429,103 ▲ 122% vs 2022 (€ 193,296) Unchanged	€ 357,920 Balance sheet total 2024: € 357,920 ▼ 17% vs 2023 (€ 429,103) Unchanged	€ 153,057 Balance sheet total 2025: € 153,057 ▼ 57% vs 2024 (€ 357,920) Unchanged	▼ 57%

Key figures of RIXPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to RIXPHARMA?

What happened at RIXPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 27, 2026 New annual accounts for financial year 2025: loss of € 5,655. filed late Source: NBB ↗
Jul 17, 2006 New establishment in Rixensart. KBO
Jun 26, 2006 Start of the company according to the CBE. KBO

In short

From € 4,213 loss in 2022 to € 5,655 loss in 2025.

Best year ever: 2023, with € 7,253 profit.

Original PDFs at the National Bank ↗

A new publication or filing at RIXPHARMA? We notify you, reason included.

Follow RIXPHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Thibault Bataille

RIXPHARMA

Behind RIXPHARMA is Thibault Bataille.

See the full network in the app

Directors

According to the 2025 annual accounts

Thibault Bataille

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Avenue John Kennedy 45

1330 Rixensart

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0882.172.240
VAT number: BE 0882.172.240
Registered office: Avenue John Kennedy 45, 1330 Rixensart
Names & denominations: RIXPHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 26 June 2006
Peppol: Active · Active since 3 Mar 2026

View on CBE Public ↗ Annual accounts (NBB) ↗